In prior posts,”Xarelto Fatalities and Serious Side Effects” and “Xarelto Fatalities, Deaths, Side Effects and Growing Market Share as Lawsuits Mount” we explored how XARELTO (RIVAROXABAN) lawsuits were growing across the United States. The lawsuits have continued to be the subject of an ongoing investigation in our office for consumers nationwide and many cases are expected in a recently formed Multi-District Litgation as noted in “Xarelto Lawsuit MDL Formed“. A common theme in these interrelated post explains the rise in market share and identifies the population targeted by marketing efforts of manufacturers. Concerns over risks to the patient population using XARELTO (RIVAROXABAN) are well founded and arguably validated by a recent article in a JAMA publication, The Medical Letter on Drugs and Therapeutics, New Oral Anticoagulants for Acute Venous Thromboembolism.
This commentary evaluates some available data in considering the newest anticoagulants – XARELTO, PRADAXA and ELIQUIS – along with the decades old “go to” drug – COUMADIN/WARFARIN. In doing so, the commentary points out exactly what the marketing efforts of pharmaceutical giants have emphasized to date to propel their products into Blockbuster status: There is no requirement for routine testing and there are no dietary restrictions for consumers. These two factors are required by users of COUMADIN and WARFARIN to monitor for adverse side effects.
What the advertising and direct to consumer marketing do not emphasize to the average consumer is the fact that the newest and latest anticoagulants do not have a known antidote. As a result, their effects are not easily reversible and pose a higher risk for uncontrollable bleeding or side effects following a trauma. Additionally, all of the newer anticoagulants have a shorter half life which increases the risks associated with any missed doses. The Devil, as they say, is in the details.
Of most significance is the fact that, this new commentary points out the proverbial Achilles Heel for an already at risk patient population. There is limited, if any, meaningful data in any existing clinical trial for the newest anticoagulants for treatment of blood clots in patients over 75 years of age. So, the oldest and sickest patient population that may have trouble monitoring their diet or making routine exams to check their blood work are arguably left to fend for themselves in this respect.
We are investigating cases of XARELTO SIDE EFFECTS and XARELTO FATALITIES in all patient populations as part of our ongoing efforts to represent clients and protect consumers nationwide. Please call (954) 524-2820 for more information or e-mail the Author directly [email protected]